The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment <i>In Vitro</i>

The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment <i>In Vitro</i>

Osteosarcoma (OS) is a primary bone malignancy characterized by an aggressive nature, limited treatment options, low survival rate, and poor patient prognosis. Conditionally replicative adenoviruses (CRAds) armed with immune checkpoint inhibitors hold great potential for enhanced therapeutic efficac...

Full description

Bibliographic Details
Main Authors: Theresa A. Higgins, Daniel J. Patton, Isabella M. Shimko-Lofano, Timothy L. Eller, Roberto Molinari, Maninder Sandey, Aliaa Ismail, Bruce F. Smith, Payal Agarwal
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cells
Subjects:
conditionally replicative adenovirus (CRAd)
cancer immunotherapy
osteosarcoma
immune checkpoint inhibitor
oncolytic adenovirus
PD-1
Online Access:https://www.mdpi.com/2073-4409/13/4/351

Internet

https://www.mdpi.com/2073-4409/13/4/351

Similar Items